Evaluation of the Response to Ranibizumab Therapy Following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema

Overview

Journal Case Rep Ophthalmol

Specialty Ophthalmology

Date 2015 Mar 25

PMID 25802504

Citations 12

Authors

Joel Hanhart

Itay Chowers

Affiliations

Soon will be listed here.

Abstract

Background/aims: Bevacizumab and ranibizumab are routinely used to treat diabetic macular edema (DME). We aim to evaluate the usefulness of switching to ranibizumab therapy following bevacizumab treatment failure in eyes with DME.

Methods: We performed a retrospective analysis of a consecutive group of patients with DME who received ranibizumab injections following the failure of bevacizumab injections. The injections were delivered following a pro re nata protocol every 4-6 weeks. The data collected included demographics, systemic and ophthalmic findings, as well as the central subfield thickness according to spectral-domain OCT.

Results: Eight eyes (5 patients) were included in the study. The median number of bevacizumab injections prior to the switch to ranibizumab was 4, and the median number of ranibizumab injections during the study was 2. The mean follow-up period was 541 ± 258 days. The mean central retinal thickness (CRT) (±SEM) was 539 ± 75 μm before the initiation of bevacizumab treatment, and 524 ± 43 μm after the last bevacizumab injection (p = 0.7). It reduced to 325 ± 26 μm following the ranibizumab injections (p = 0.0063). The best-corrected visual acuity (BCVA) improved in 4 eyes and remained stable in 4 eyes following the ranibizumab injections.

Conclusion: A ranibizumab therapy was effective in reducing the CRT in eyes that failed bevacizumab therapy. A BCVA improvement can also occur in these eyes. Switching between anti-vascular endothelial growth factor compounds may be beneficial in eyes with DME.

Citing Articles

Cost containment by peer prior authorization program for second line treatment in patients with retinal disease.

Rosenblatt A, Hekselman I, Rosenblatt I, Hekselman I, Gaton D Isr J Health Policy Res. 2021; 10(1):4.

PMID: 33494826 PMC: 7830824. DOI: 10.1186/s13584-021-00437-1.

Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis.

Babiuch A, Conti T, Conti F, Silva F, Rachitskaya A, Yuan A Int J Retina Vitreous. 2019; 5:17.

PMID: 31367468 PMC: 6647124. DOI: 10.1186/s40942-019-0167-x.

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion.

Konidaris V, Tsaousis K, Anzidei R, Mata G, Brent A Ophthalmol Ther. 2018; 7(2):387-395.

PMID: 30288685 PMC: 6258582. DOI: 10.1007/s40123-018-0149-3.

Real-life experience of ranibizumab for diabetic macular edema in Taiwan.

Tsai M, Hsieh Y, Peng Y Int Ophthalmol. 2018; 39(7):1511-1522.

PMID: 29926364 DOI: 10.1007/s10792-018-0970-7.

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab.

Nixon D, Flinn N Clin Ophthalmol. 2018; 12:191-197.

PMID: 29403260 PMC: 5784749. DOI: 10.2147/OPTH.S158268.

References

Gasperini J, Fawzi A, Khondkaryan A, Lam L, Chong L, Eliott D . Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2011; 96(1):14-20. DOI: 10.1136/bjo.2011.204685. View

Fernando Arevalo J, Lasave A, Wu L, Diaz-Llopis M, Gallego-Pinazo R, Alezzandrini A . Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months. Retina. 2012; 33(2):403-13. DOI: 10.1097/IAE.0b013e3182695b83. View

Sivaprasad S, Crosby-Nwaobi R, Heng L, Peto T, Michaelides M, Hykin P . Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5). Br J Ophthalmol. 2013; 97(9):1177-80. DOI: 10.1136/bjophthalmol-2013-303168. View

Chong V . Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica. 2012; 227 Suppl 1:2-10. DOI: 10.1159/000337152. View

Labriola L, Sadda S . Rapid resolution of macular edema associated with central retinal vein occlusion using ranibizumab after failure with multiple bevacizumab injections. Semin Ophthalmol. 2011; 26(6):387-91. DOI: 10.3109/08820538.2011.622339. View

Brown D, Kaiser P, Michels M, Soubrane G, Heier J, Kim R . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432-44. DOI: 10.1056/NEJMoa062655. View

Kent J, Iordanous Y, Mao A, Powell A, Shukla Kent S, Sheidow T . Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Can J Ophthalmol. 2012; 47(2):159-64. DOI: 10.1016/j.jcjo.2012.01.003. View

Beck R, Edwards A, Aiello L, Bressler N, Ferris F, Glassman A . Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009; 127(3):245-51. PMC: 2754047. DOI: 10.1001/archophthalmol.2008.610. View

Kuhn T . [Results of an expert survey on VEGF inhibitors in ophthalmology]. Klin Monbl Augenheilkd. 2011; 228(7):607-12. DOI: 10.1055/s-0029-1245827. View

10.

Aiello L, Bursell S, Clermont A, Duh E, Ishii H, Takagi C . Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997; 46(9):1473-80. DOI: 10.2337/diab.46.9.1473. View

11.

Nguyen Q, Shah S, Khwaja A, Channa R, Hatef E, Do D . Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010; 117(11):2146-51. DOI: 10.1016/j.ophtha.2010.08.016. View

12.

Lang G, Berta A, Eldem B, Simader C, Sharp D, Holz F . Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology. 2013; 120(10):2004-12. DOI: 10.1016/j.ophtha.2013.02.019. View

13.

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

14.

Massin P, Bandello F, Garweg J, Hansen L, Harding S, Larsen M . Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010; 33(11):2399-405. PMC: 2963502. DOI: 10.2337/dc10-0493. View

15.

Ehlken C, Jungmann S, Bohringer D, Agostini H, Junker B, Pielen A . Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond). 2014; 28(5):538-45. PMC: 4017123. DOI: 10.1038/eye.2014.64. View

16.

Elman M, Qin H, Aiello L, Beck R, Bressler N, Ferris 3rd F . Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012; 119(11):2312-8. PMC: 3490003. DOI: 10.1016/j.ophtha.2012.08.022. View

17.

Nepomuceno A, Takaki E, de Almeida F, Peroni R, Cardillo J, Siqueira R . A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013; 156(3):502-510.e2. DOI: 10.1016/j.ajo.2013.04.026. View

18.

Eghoj M, Sorensen T . Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2011; 96(1):21-3. DOI: 10.1136/bjo.2011.203893. View

19.

Aiello L, Beck R, Bressler N, Browning D, Chalam K, Davis M . Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011; 118(12):e5-14. PMC: 3253487. DOI: 10.1016/j.ophtha.2011.09.058. View

20.

Ozturk B, Kerimoglu H, Bozkurt B, Okudan S . Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther. 2011; 27(4):373-7. DOI: 10.1089/jop.2010.0195. View